MESO
Mesoblast Limited
There isn't enough reported data to score MESO yet.
MESO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MESO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
MESO PE Valuation
MESO has no meaningful PE right now: it lost money over the past year.
MESO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect MESO's losses to grow, with revenue declining.
MESO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.07 | +$0.02 |
| Q2 2025 | -$0.08 | +$0.05 |
| Q4 2024 | -$0.09 | +$0.09 |
| Q2 2024 | -$0.13 | +$0.08 |
| Q4 2023 | -$0.18 | +$0.05 |
| Q2 2020 | -$0.28 | +$0.06 |
| Q2 2019 | -$0.34 | -$0.20 |
MESO is still losing money, but far less than before: $0.07 per share over the past year, against $0.34 at its worst in mid-2019.
MESO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $51.3M | +1527% |
| Q2 2025 | $14M | +459% |
| Q4 2024 | $3.2M | -6.8% |
| Q2 2024 | $2.5M | +18% |
| Q4 2023 | $3.4M | +59% |
| Q2 2023 | $2.1M | -3.9% |
| Q1 2023 | $1.9M | -3.6% |
| Q4 2022 | $2.1M | -10% |
MESO's revenue has grown year over year for five quarters in a row: $51M last quarter, up 1415% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -77% | +886 points |
| Q2 2025 | -385% | +641 points |
| Q4 2024 | -1512% | -551 points |
| Q2 2024 | -2208% | -1057 points |
| Q4 2023 | -963% | +164 points |
| Q2 2023 | -1027% | -60 points |
| Q1 2023 | -962% | +100 points |
| Q4 2022 | -1151% | -59 points |
MESO's operating margin was −77% last quarter, up 886 points from the same quarter a year ago, near the top of its range since 2018.
MESO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$30.8M | -$10M |
| Q4 2024 | -$20.8M | +$5.8M |
| Q1 2023 | -$16.3M | -$731K |
MESO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +84.3M shares |
| 1 year | +203% | +866M shares |
| 3 years | +277% | +949M shares |
| 5 years | +389% | +1B shares |
| Available history | +424% | +1B shares |
MESO has 1.3B diluted shares, up 203% from a year ago.
MESO Net Leverage
MESO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MESO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.2 | Neutral |
| Stochastic | 35.5 | Neutral |
MESO's weekly RSI is 43 (neutral) and its Stochastic is 36 (neutral).
MESO PE vs Healthcare Sector
MESO has no meaningful PE right now: it lost money over the past year.
MESO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 6.1% below |
| 20 week MA | $15.1 | 13% below |
| 50 week MA | $15.7 | 17% below |
| 100 week MA | $15.2 | 14% below |
| 200 week MA | $10.5 | 25% above |
MESO has fallen below most of its moving averages, though it's still 25% above its 200-week average.
MESO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $17.5 | +18% |
| 2021 | $17.5 | $9.64 | -45% |
| 2022 | $9.64 | $5.95 | -38% |
| 2023 | $5.95 | $2.20 | -63% |
| 2024 | $2.20 | $17.5 | +697% |
| 2025 | $17.5 | $19.5 | +11% |
| 2026 YTD | $19.5 | $13.1 | -33% |
MESO's yearly returns have swung widely, from +697% in 2024 to −63% in 2023. It's down 33% so far in 2026.